Vital Therapies, a clinical-stage biotech developing treatments for acute liver failure, announced terms for its IPO on Wednesday. The San Diego, CA-based company plans to raise $75 million by offering 4.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Vital Therapies would command a market value of $277 million.
Vital Therapies, which was founded in 2003, plans to list on the NASDAQ under the symbol VTL. Vital Therapies initially filed confidentially on July 22, 2013. Credit Suisse and William Blair are the joint bookrunners on the deal.
